Skip to main content
Premium Trial:

Request an Annual Quote

Europe s Affitech, Axaron Form Alliance to Develop Antibodies

NEW YORK, Dec. 4 – Affitech of Oslo and Axaron Bioscience of Heidelberg, Germany, said Tuesday that they had agreed to jointly develop and sel antibody drugs for neurological disorders. 

Axaron, formerly known as BASF-Lynx Bioscience, will use its transcription profiling technologies to identify targets that Affitech will then use in the development of antibodies. Both companies will support the effort to bring the antibodies through preclinical and clinical trials.

Affitech will have ownership of the antibodies, while Axaron, which will contribute some of the development costs, could be entitled to up to two-thirds of the profits from any products that are commercialized.  

The companies did not offer any specifics about the financial terms of the agreement.

Ole Marvik, CEO of Affitech, called the alliance “an excellent exsample of technical and commercial synergies.”

Established in 1997, Affitech generates human antibodies using an in vitro selection process.

Axaron grew out of a joint venture between German chemicals giant BASF and Lynx Therapeutics, an American maker of DNA profiling technologies.

The company's offerings are based on technologies developed in house as well as those licensed from Lynx Therapeutics, including Megaclone, a system that uses microbeads to sort millions of DNA molecules according to sequence, and Massively Parallel Signature Sequencing technology, which can identify genes by a 16 to 20 base signature sequence.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.